Astellas, J&J Link For Arthritis Drug | Chemical & Engineering News
Volume 90 Issue 41 | p. 21 | Concentrates
Issue Date: October 8, 2012

Astellas, J&J Link For Arthritis Drug

Department: Business
Keywords: pharmaceuticals, arthritis, JAK inhibitors, Japan

Janssen Biotech, the R&D arm of Johnson & Johnson, will pay Japan’s Astellas Pharma $65 million for access to ASP015K, a JAK inhibitor in Phase II trials as a rheumatoid arthritis treatment. Janssen, which gains rights to develop the small-molecule compound everywhere but Japan, will pay for future clinical studies. Astellas could reap another $880 million in milestone and royalty payments if ASP015K reaches the market. Pfizer is awaiting FDA approval for tofacitinib, its own JAK inhibitor for arthritis.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment